MedWire News -- Results from an analysis of the TREAT study suggest that diabetes patients with chronic kidney disease (CKD) and moderate anemia who had a poor response to the anemia drug darbepoetin alfa were more likely to have an adverse cardiovascular (CV) outcome than those with a better response, despite receiving a higher mean dose.
